Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.293
EU - Europa 2.734
AS - Asia 2.010
SA - Sud America 107
AF - Africa 15
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.191
SG - Singapore 777
IE - Irlanda 609
CN - Cina 518
IT - Italia 499
HK - Hong Kong 475
SE - Svezia 404
RU - Federazione Russa 400
DE - Germania 393
GB - Regno Unito 119
CA - Canada 97
UA - Ucraina 92
BR - Brasile 91
IN - India 54
AT - Austria 51
FI - Finlandia 49
ID - Indonesia 46
VN - Vietnam 42
DK - Danimarca 38
TR - Turchia 35
FR - Francia 20
BE - Belgio 19
JP - Giappone 14
NL - Olanda 11
KR - Corea 10
IR - Iran 8
PL - Polonia 8
BD - Bangladesh 7
AR - Argentina 5
RO - Romania 5
ES - Italia 4
MU - Mauritius 4
SA - Arabia Saudita 4
TW - Taiwan 4
UY - Uruguay 4
AM - Armenia 3
IQ - Iraq 3
AU - Australia 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
JO - Giordania 2
MX - Messico 2
NG - Nigeria 2
PE - Perù 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
DZ - Algeria 1
ET - Etiopia 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 12.164
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.331
Fairfield 850
Dublin 601
Ashburn 559
Singapore 483
Woodbridge 481
Hong Kong 463
Wilmington 430
Seattle 385
Chandler 372
Cambridge 320
Houston 318
Frankfurt am Main 264
Princeton 248
New York 245
Jacksonville 163
Santa Clara 129
Altamura 122
Shanghai 121
Lawrence 118
Beijing 103
Milan 90
San Diego 71
Dearborn 63
Toronto 46
Jakarta 45
Andover 44
Vienna 41
Boardman 34
Helsinki 33
London 32
Nanjing 32
Guangzhou 29
Hangzhou 27
Ottawa 25
Turin 25
Dallas 23
Falls Church 23
Dong Ket 22
Pune 22
Washington 22
Council Bluffs 19
Nuremberg 19
Brussels 18
Norwalk 18
Rome 16
Los Angeles 15
Tianjin 14
Hebei 13
Jinan 13
Redmond 13
Lachine 12
Munich 12
Torre Del Greco 12
Zhengzhou 11
Tappahannock 10
Chicago 8
Perugia 8
Phoenix 8
Edmonton 7
Fremont 7
Genoa 7
Lissone 7
Nanchang 7
Kilburn 6
Kowloon 6
Mountain View 6
Shenyang 6
Torino 6
Carignano 5
Lodz 5
Mumbai 5
Ningbo 5
Prescot 5
Rio de Janeiro 5
San Mateo 5
São Paulo 5
Bari 4
Changsha 4
Desio 4
Hefei 4
Izmir 4
Jiaxing 4
Kunming 4
Laurel 4
New Bedfont 4
Tokyo 4
Wuhan 4
Amsterdam 3
Bergamo 3
Bologna 3
Bonndorf 3
Broni 3
Camogli 3
Changchun 3
Guarulhos 3
Hanoi 3
Huizen 3
Kocaeli 3
Lappeenranta 3
Totale 9.279
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 317
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 269
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 257
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 247
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 245
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 235
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 229
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 223
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 223
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 205
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 199
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 190
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 187
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 185
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 174
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 169
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 163
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 163
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 157
When progressive dysphagia could be related to an “old friend” – a case report 150
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 147
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 147
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 143
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 139
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 137
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 134
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 131
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 130
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 121
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 120
Novel cytotoxic chemotherapies in small cell lung carcinoma 119
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 108
Drugs ten years later: epirubicin 108
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 108
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 107
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 106
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 103
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 101
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 100
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 98
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 98
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 98
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 97
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 97
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 97
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 93
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 93
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 92
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 91
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 91
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 90
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 89
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 89
Focus on nivolumab in NSCLC 87
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 85
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 85
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 85
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 84
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 84
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 83
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 82
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 82
Oxaliplatin doublets in non-small cell lung cancer: A literature review 81
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 81
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 80
Pilot study with adriamycin and ifosfamide in small cell lung cancer 80
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 79
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 79
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 79
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 79
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 78
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 78
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 77
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 75
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 74
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 73
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 72
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 72
Esophageal carcinoma: radiochemotherapy 71
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 71
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 71
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 71
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 70
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 70
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 69
Targeted therapies and immunotherapy in non-small-cell lung cancer 69
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 69
Combined radiation and chemotherapy in esophageal cancer 69
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 69
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 69
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 68
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset 68
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 65
Isolated cardiac metastasis from squamous cell esophageal cancer 65
Small cell lung cancer 65
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 65
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 65
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 65
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 64
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 64
Totale 11.295
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020974 0 0 0 0 0 0 0 0 406 252 236 80
2020/20212.579 132 136 324 240 137 185 293 324 219 220 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20252.240 219 500 198 171 301 132 213 80 426 0 0 0
Totale 12.772